Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
about
Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patientsThe impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.Multi-kinase inhibitors, AURKs and cancer.Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
P2860
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Second-line treatment of non-s ...... or tyrosine kinase inhibitors?
@en
Second-line treatment of non-s ...... or tyrosine kinase inhibitors?
@nl
type
label
Second-line treatment of non-s ...... or tyrosine kinase inhibitors?
@en
Second-line treatment of non-s ...... or tyrosine kinase inhibitors?
@nl
prefLabel
Second-line treatment of non-s ...... or tyrosine kinase inhibitors?
@en
Second-line treatment of non-s ...... or tyrosine kinase inhibitors?
@nl
P2093
P2860
P356
P1476
Second-line treatment of non-s ...... or tyrosine kinase inhibitors?
@en
P2093
Antonio Passaro
Enrico Cortesi
Filippo de Marinis
P2860
P304
P356
10.1586/ERA.11.120
P577
2011-10-01T00:00:00Z